Vesalius Biocapital offers venture capital
to young European innovative life science companies

Investment philosophy

Each of us is an expert in a specific sector of the life sciences. Having worked in the industry, our hands-on experience allows for critical judgment of the science and technology and the knowledge to create successful businesses.
We sit on the board of the companies we finance and we play an active role during every growth stage of the company. Given our team is relative small we can act in a cohesive way and quickly in order to make decisions swiftly.
We invest in all sectors of the life sciences, including therapeutics, medical devices and diagnostics.
Our major investment criteria are the following:

  • Uniqueness of the R&D pipeline in terms of addressing significant medical need or innovative technologies improving the cost-efficiency of drug discovery and drug development.
  • Patent protection or anticipated patent protection of key elements of R&D pipeline and technologies.
  • Sizeable and growing market or niche market in premium price segment.
  • Strategically thinking management team with preferably a background in pharmaceutical industry and a strong operational track record in product- and business development.
  • Common understanding on value creation.

Our investment process is composed of several steps:

  • Our initial review is mostly centered around dialogue with the founders and management. You should be able to present the different challenges and risks of your project. This may take several meetings if the case looks promising. In a second stage, we will brainstorm with the founders and management around key strategic issues including business model, financing strategy and recruitment needs.
  • Once we feel comfortable with the different aspects of the business case, we will start full due diligence, including expert opinions from leaders in the field. A binding term sheet will be negotiated and syndication of the deal pursued. Legal and accounting audits will be done.